Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
暂无分享,去创建一个
L. Kappos | E. Leray | J. Lechner-Scott | M. Slee | A. Al-Asmi | S. Vukusic | F. Grand'Maison | V. Shaygannejad | E. Thouvenot | E. Havrdová | H. Butzkueven | P. Cabre | S. Khoury | G. Edan | R. Gouider | C. Malpas | F. Patti | A. van der Walt | G. Izquierdo | M. Amato | A. Wahab | K. de Gans | Y. Fragoso | C. Boz | S. Bakchine | D. Laplaud | B. Stankoff | S. Vucic | P. Mccombe | M. Debouverie | T. Moreau | O. Gout | J. Pelletier | A. Prat | P. Clavelou | M. Girard | S. Ozakbas | D. Horáková | T. Kalincik | P. Grammond | V. van Pesch | R. Alroughani | K. Buzzard | O. Skibina | E. Cartechini | O. Heinzlef | R. Macdonell | P. Labauge | J. de Seze | J. Ciron | E. Maillart | H. Zéphir | B. Bourre | T. Castillo-Triviño | C. Lebrun-Frénay | S. Hodgkinson | E. Berger | C. Labeyrie | J. Sotoca | I. Roos | S. Eichau | J. Prevost | G. Laureys | L. Van Hijfte | E. Butler | R. Casey | M. Terzi | D. Spitaleri | A. Soysal | E. Aguera-Morales | R. Turkoglu | Y. Sidhom | T. Csépány | N. Maubeuge | C. Ramo-Tello | B. Yamout | R. Ampapa | Michael H Barnett | J. Sánchez-Menoyo | O. Gerlach | Michael H. Barnett | Nasr Haifa Ben
[1] T. Derfuss,et al. Lymphocyte recovery after fingolimod discontinuation in patients with MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[2] D. Arnold,et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials , 2020, JAMA neurology.
[3] K. Anja. European Committee for Treatment and Research in Multiple Sclerosis , 2019, Kinder- und Jugendmedizin.
[4] J. Lechner-Scott,et al. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. , 2019, Multiple sclerosis and related disorders.
[5] C. Tornatore,et al. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations , 2019, Neurology and Therapy.
[6] H. Butzkueven,et al. The MSBase registry: Informing clinical practice , 2019, Multiple sclerosis.
[7] L. Kappos,et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[8] R. Kinkel,et al. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis , 2019, Therapeutic advances in neurological disorders.
[9] F. Guillemin,et al. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France , 2018, Multiple sclerosis.
[10] V. Meca-Lallana,et al. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. , 2018, Multiple sclerosis and related disorders.
[11] L. Kappos,et al. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy , 2018, Journal of the Neurological Sciences.
[12] R. Grasso,et al. Clinical activity after fingolimod cessation: disease reactivation or rebound? , 2018, European journal of neurology.
[13] M. Reindl,et al. Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors , 2017, Multiple sclerosis.
[14] F. Lublin,et al. The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies. , 2017, Multiple sclerosis and related disorders.
[15] T. Friede,et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[16] M. Tsolaki,et al. Data quality evaluation for observational multiple sclerosis registries , 2017, Multiple sclerosis.
[17] M. Clanet,et al. Risk of relapse after natalizumab withdrawal , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[18] E. Waubant,et al. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. , 2016, JAMA neurology.
[19] H. Butzkueven,et al. Observational data: Understanding the real MS world , 2016, Multiple sclerosis.
[20] L. Kappos,et al. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis , 2016, Multiple sclerosis.
[21] Pierre Grammond,et al. Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.
[22] D. Centonze,et al. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads , 2015, Multiple sclerosis.
[23] R. Wilson. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study , 2015, Neurology.
[24] P. Sørensen,et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients , 2014, Journal of Neurology.
[25] J. Lechner-Scott,et al. Fingolimod after natalizumab and the risk of short-term relapse , 2014, Neurology.
[26] L. Kappos,et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy , 2014, Multiple sclerosis.
[27] X. Montalban,et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab , 2012, Multiple sclerosis.
[28] K. Rammohan,et al. WriteClick: Editor’s Choice DISEASE ACTIVITY RETURN DURING NATALIZUMAB TREATMENT INTERRUPTION IN PATIENTS WITH MULTIPLE SCLEROSIS , 2011 .
[29] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[30] S. Cole,et al. Time scale and adjusted survival curves for marginal structural cox models. , 2010, American journal of epidemiology.
[31] Stephen R Cole,et al. Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.
[32] E. Leray,et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[33] L. Kappos,et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.
[34] S. Vukusic,et al. Age at disability milestones in multiple sclerosis. , 2006, Brain : a journal of neurology.
[35] S. Vukusic,et al. Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.
[36] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[37] H. Hartung,et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.
[38] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[39] C Confavreux,et al. Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.
[40] F. Mcdowell,et al. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[41] Edmus Coordinating. Natural history of multiple sclerosis: A unifying concept , 2006 .